Note: Descriptions are shown in the official language in which they were submitted.
METHODS AND COMPOSITIONS FOR TREATMENT OF EPITHELIAL WOUNDS IN
DIABETIC SUBJECTS
FIELD OF THE INVENTION
[0001] This invention relates to treatment of epithelial wounds.
[0002] The invention provides, in particular methods and formulations for
treating epithelial wounds
based on application of opioid antagonists such as naltrexone.
BACKGROUND OF THE INVENTION
[0003] Wound healing is a carefully orchestrated series of events with
overlapping temporal and
spatial relationships, and includes phases of inflammation, proliferation, and
remodeling (Guo et at.,
Journal Dent Res, 89:219-229 (2010); Shih et al., Wound Repair Regeneration,
18: 139-153 (2010)).
Some of the processes in wound repair that have been implicated as responsible
factors include
abnormalities in inflammation, migration, angiogenesis, neovascularization,
cell proliferation,
formation of granulation tissue and collagen, and re-epithelialization (Usui
et al., Journal of
Histochem Cytochem, 56:687-696 (2008); Mustoe et al, American Journal of
Surgery, 187:655-705
(2004); Brem et al., Arch Surg, 135:627-634 (2000)).
[0004] In Type 1 diabetes, wounds often fail to progress through the normal
stages of healing
(Boulton et al., Lancet, 366: 1719-1724 (2005); Usui et at., Journal of
Histochem Cytochem, 56:687-
696 (2008)). Impaired wound healing is a major complication of diabetes that
can result in the
formation of chronic debilitating ulcers (Guo et al., Journal Dent Res, 89:219-
229 (2010); Boulton et
al., Lancet, 366: 1719-1724 (2005); O'Loughlin et al., International Journal
of Lower Extremity
1
CA 2842337 2019-06-17
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
Wounds, 9:90-102 (2010)), accounting for over 50% of patients having lower
extremity
amputations annually. With the number of diabetic patients estimated to reach
300 million
world-wide by the year 2030, the burden of diabetic wounds and their
complications is expected
to rise simultaneously (Boulton et al., Lancet, 366:1719-1724 (2005)).
Although continuing
medical care and patient self-management reduce the risk of long-term
complications, and
despite the availability of numerous dressing products, there is no fully
effective prevention or
treatment of these complications.
[0005] Initially studied for their role as neurotransmitters (Akil et al., Ann
Rev Neuroscience,
7:223-255 (1984)), endogenous opioids have been shown to be present in neural
and non-neural
tissues, and to mediate a number of functions other than neuromodulation
including cell
proliferation, angiogenesis, tissue organization, cell migration, and immunity
(Zagon et al.,
Journal of Invest Dermatology, 106:490-497 (1996); Zagon et al., Diabetes,
51:3055-3062
(2002); Zagon et al., Journal of Vascular Surgery, 37:636-643 (2003); Blebea
et al., Journal of
Vascular Surgery. 32:364-373 (2000); Zagon et al., hntnunobiology, 216:173-183
(2011); Zagon
et al., Immunobiology, 216:579-590 (2011); Wilson et al., Cell Prolif, 33:63-
73 (2000)). The
endogenous opioids include dynorphins, enkephalins, endorphins, endomorphins
and nociceptin.
Classical opioid receptors are the IA, & and K receptors; non-classical opioid
receptors include the
nociceptin receptor and the opioid growth factor receptor (OGFr), also
referred to as the c (zeta)
receptor (Corbett et al. Br. J. Pharmacol. 147 Suppl 1: S153-62 (2006)). The
endogenous ligand
for OGFr is [Met51-enkephalin, also called opioid growth factor (OGF).
[0006] The relationship of native opioids to diabetes has received some
attention. Studies
concerned with circulating opioid levels in diabetes have shown that patients
with type 1 diabetes
(T ID) have high plasma [Met5]-enkephalin levels (Fallucca et al., Metabolism,
45:1065-1068
(1996); Negri et al., Metabolism, 41:460-461 (1992); Kolta et al.,
Neuropeptides, 21:55-63
(1992)). Elevated levels of [Met]-enkephalin also have been reported in plasma
of genetically
obese diabetic (db/db) mice (Timmers et al., Diabetes, 35:1143-1151(1986):
Greenberg et al.
Endocrinology. 116:328-331(1985)).
2
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
[0007] A series of studies using systemic and topical applications of the
opioid antagonist
naltrexone (NTX) in rats with T ID reported delays in re-epithelialization
following removal of
ocular surface epithelium that were reversed by NTX and related to an increase
in DNA
synthesis (Zagon et al., Diabetes, 51:3055-3062 (2002); Klocek et al., Journal
of Ocular
Pharmacology and Therapeutics, 23:89-102 (2007)). These data suggest that
dysfunctional
ocular wound repair in T ID was due to an increase in opioid peptide-opioid
receptor interactions
that were disrupted by NTX. OGF is known to suppress re-epithelialization in
the human cornea
(Zagon et al., Investigative Ophthalmology & Visual Science, 41:73-81 (2000))
and rat tail skin
(Wilson et al., Cell Prolif 33:63-73 (2000)).
[0008] Endogenous opioids, and classical and non-classical opioid receptors,
are present in
epithelial tissues (Cheng et al., Clin Lab Invest, 158:713-720 (2008); Wintzen
et al., Exp
Dermatol, 10:305-311 (2001); Tominaga Journal of Invest Dermatol, 127:2228-
2235 (2007);
Bigliardi-Qi et al., Differentiation, 74:174-185 (2006); Nissen et al.,
Experimental Dermatology,
6:222-229 (1997); Wenk et al., Journal of Comp Neurol, 408:567-579 (1999);
Salemi et al.,
Biochem Bioplzys Res Commun, 338:1012-1017 (2005); Zagon et al., Cell Tissue
Research,
246:561-565 (1986); Bigliardi et al., Journal of Invest Dermatol, 111:297-
301(1998); Kauser et
al., Journal of Invest Dermatol, 120:1073-1080 (2003)), OGF is known to
regulate DNA
synthesis and cellular renewal of the stratum corneum, (Wintzen et al., Exp
Dermatol, 10:305-
311(2001)) whereas deletion of the 6 opioid receptor in mice alters skin
differentiation and
delays wound healing (Bigliardi-Qi et al., Differentiation, 74:174-185
(2006)).
[0009] There is an urgent need to understand the pathophysiology underlying
wound healing in
diabetes and other situations in which wound healing is delayed, and to
translate this knowledge
into treatment modalities in order to prevent or at least attenuate acute and
chronic wound
healing complications (Usui et al., Journal of Histochem Cytochem, 56:687-696
(2008)).
3
SUMMARY OF THE INVENTION
[0010] In one embodiment, the present invention is directed to a method of
treating epithelial
wounds by administering an effective amount of an opioid antagonist to a
subject in need
thereof. In a specific embodiment, the opioid antagonist being administered is
naltrexone. In
another specific embodiment, the opioid antagonist being administered is
naloxone.
[0011] In another embodiment, the present invention provides a composition for
the treatment of
epithelial wounds, which contains an effective amount of an opioid antagonist
and a
pharmaceutically acceptable carrier suitable for topical administration. In a
specific
embodiment, the opioid antagonist provided in the composition is naltrexone.
In another specific
embodiment, the opioid antagonist being administered is naloxone.
BRIEF DESCRIPTION OF THE DRAWINGS
100121 Figure 1. Body weights (A) and glucose levels (B) of rats rendered
diabetic with STZ
(D13) or those untreated receiving saline (Normal). A: Body weights were
recorded prior to
STZ injection (week 0), and weekly thereafter. B: Blood glucose levels were
recorded before
(week 0) and at I, 4, and 8 weeks after STZ administration. Values represent
means + SEM for at
least 5 animals/group at each time point. Significantly different from Normal
at **P < 0.01
and ***P <0.001.
[0013] Figure 2. Histograms of the labeling indexes in stratum basale on the
dorsum of rats
topically treated with NTX (10 M, l05 M, or 10" M) dissolved in Sorenson's
phosphate
buffer (SPB), DMSO, KY Jelly (trademark) (KYJ), or Neutrogena (trademark)
moisturizing
cream (MCN); control rats received the corresponding vehicle (Vehicle).
Animals received 3
topical applications of NTX. At 3 and 6 hr before euthanasia, animals received
injections of
BrdU (100 mg/kg; i.p.). Two-way ANOVA for Treatment (4 carriers and 4
concentrations/carrier) and Condition (diabetic, Normal) was performed. There
was no overall
effect for Condition; Treatment was significant at P<0.001, F=5.59 (15, 288).
Data represent
means + SEM. Based on one-way ANOVA for
4
CA 2842337 2018-10-09
each carrier and Condition, significantly different from respective values for
vehicle-treated rats at
*P < 0.05, **P < 0.01. and ***P < 0.001.
[0014] Figure 3. Histological preparations of dorsal skin from Normal and
Diabetic rats subjected to
10"5 M NTX in Neutrogena (trademark) moisturizing cream (MCN+NTX),
moisturizing cream only
(MCN+ Vehicle), or no treatment. Sections were stained with anti-BrdU
antibodies and
counterstained with hematoxylin. Note increases in BrdU-positive cells (arrow)
in the NTX-treated
groups, bl, basal layer; epi, epidermis; de, dermis. Bar = 12 1.1111.
[0015] Figure 4. Photomicrographs of full-thickness wounds created on the
dorsal surface of Normal
and Diabetic rats. Wounds were treated 3 times daily with either 10"5 M NTX
dissolved in
Neutrogena (trademark) moisturizing cream (MCN+NTX) or moisturizing cream
alone (MCN+
Vehicle) and photographed on day 0, 3, 5. 7, and 9 following wounding. Bar = 6
mm.
[0016] Figure 5. Histograms of residual defects (%) in rat skin after
formation of 6 mm wounds and
followed for 9 days. A. Normal and Diabetic (DB) rats receiving no treatment.
B. Normal and
Diabetic rats treated one time (1x) or 3 times (3x) daily with 10"5 M NTX
dissolved in Neutrogena
(trademark) moisturizing cream (MCN+NTX lx; MCN+NTX 3x) or receiving vehicle
alone (MCN+
Vehicle lx; MCN+ Vehicle 3x). C. The contribution of contraction and re-
epithelialization to wound
closure at 8 days in DB and Normal (N) rats treated with MCN+NTX or
MCN+Vehicle. Values
represent means + SEM. Significantly different from Normal or MCN+Vehicle at
*P <0.05, **P <
0.01, and ***P < 0.001; ++P<0.01.
100171 Figure 6. Histograms of residual defects (%) in rat skin after
formation of 6 mm wounds and
followed for 9 days. Groups included Normal and Diabetic rats treated 3 times
(3x) daily with 105
M NTX dissolved in Oil of Olay (trademark) moisturizing cream (MCOO+NTX 3x) or
receiving
vehicle alone (MCOO+Vehicle 3x), or 10"5 M NTX dissolved in KY jelly (KYJ+NTX
3x) or KY
jelly (trademark) alone (KYJ+Vchicle 3x). Values represent means + SEM.
Significantly different
from the respective vehicle at *P < 0.05, **I) <0.01, ***P <0.001.
CA 2842337 2018-10-09
[0018] Figure 7. Photomicrographs of skin from Normal and Diabetic rats
collected 20 days
after the creation of 6 mm full-thickness wounds. Some wounds were treated 3
times daily
with 10-5 M NTX dissolved in Neutrogena (trademark) moisturizing cream (MCN +
NTX) or
receiving vehicle alone (MCN + Vehicle). Sections were stained with
hematoxylin and eosin.
epi, epidermis; de, dermis. Bar = 12 Histograms of epithelial thickness
(1uri) measured
20 days after wounding. Values represent means + SEM. Significantly different
from
N/MCN + Vehicle at ***P <0.001.
[0019] Figure 8. Histograms of the labeling indexes of basal epithelial cells
in skin adjacent
to and peripheral to wounds in Normal and Diabetic rats after topical
treatment 3 times daily
with 105 M NTX dissolved in Neutrogena (trademark) moisturizing cream (MCN+
NTX 3x)
or receiving vehicle alone (MCN+ Vehicle 3x); data were collected after 5 or
10 days of
treatment. Values represent means + SEM. Significantly different from their
respective
vehicle at * P <0.05 and **P <0.01.
[0020] Figure 9. Body weights and blood glucose levels of 8-week old Type 2
diabetic
(db/db) mice and wildtype C57B1/6 mice. Mice were purchased from Jackson
Laboratories
and housed under standard laboratory care. Tail vein blood was obtained and
glucose levels
were measured by a TrueTrak glucometer. Values represent means + SEM; n= 6-10
mice/treatment group. Data were analyzed using t-tests; significantly
different from wildtype
at p<0.001 (***).
[0021] Figure 10. Residual defect (%) on days 3, 6, 13, and 15 following
formation of a 5-
mm circular full-thickness cutaneous wound created on' the dorsum of Type 2
diabetic
(db/db) and wildtype mice. Db/db mice were treated with either 10"5 M
Naltrexone (NTX) in
moisturing cream (vehicle), or vehicle alone; wildtype mice received vehicle
only.
Applications were made 3 times daily for 15 days. Values represent means + SEM
for at least
wounds/treatment group at each time point. Significantly different from
wildtype vehicle
values at p<0.01 (++). Significantly different from db/db vehicle values at
p<0.05 (*).
6
CA 2842337 2018-10-09
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
DETAILED DESCRIPTION OF THE INVENTION
[0022] It has been surprisingly discovered by the inventors that topical
administration of general
or broad-based opioid antagonists can enhance and accelerate epithelial wound
healing in both
normal and diabetic subjects, and can restore the delayed rate of wound
healing in diabetes to the
rate in normal subjects. Accordingly, the present invention provides
therapeutic methods and
topical formulations for treating epithelial wounds in a subject, including
especially a diabetic
subject, based on use of naltrexone and other general opioid antagonists.
[0023] General opioid antagonists, such as naltrexone (also abbreviated herein
as "NTX") and
naloxone, are known as broad-based antagonists of opioid receptors and are
used primarily in the
management of dependence on drugs (e.g., opioids), alcohol, and nicotine. The
beneficial effects
of opioid antagonists on the wound healing process identified herein are
surprising, especially in
light of the reports that naltrexone is a poor penetrator of the skin (see,
e.g., Stinchcomb et al., J.
Pharmaceutical Sciences 91: 2571-2578, 2002); Krishman et at., J.
Pharmaceutical Sciences 99:
2724-2731. 2010).
[0024] As disclosed herein, a marked increase in DNA synthesis of the stratum
basale in skin
was observed in diabetic animals exposed to NTX. At least one endogenous
opioid system, the
opioid growth factor -opioid growth factor receptor (OGF-OGFr) system, is
known to tonically
regulate cell proliferation through an increase in the cyclin dependent
inhibitory kinase pathway
(Cheng et al., Molecular Biology of the Cell, 20:319-327 (2009)). The OGF-OGFr
axis has been
reported to depress T - and B-cell proliferation (Zagon et al.,
Itnmutzobiology, 216:173-183
(2011); Zagon et al., Immunobiology, 216:579-590 (2011)), cell migration
(Zagon et al.,
American Journal of Physiology, 268:R942-R950 (1995)), proliferation of
keratinocytes and
fibroblasts (Zagon et al., Journal of Invest Dermatology, 106:490-497 (1996);
Zagon et al.,
Diabetes, 51:3055-3062 (2002); Zagon et al., Journal of Vascular Surgery.
37:636-643 (2003);
Blebea et al., Journal of Vascular Surgery, 32:364-373 (2000); Zagon et al.,
Immutwbiology,
216:173-183 (2011); Zagon et al., Immunobiology, 216:579-590 (2011); Wilson et
al., Cell
Pmlif, 33:63-73 (2000); Zagon et al., Investigative Ophthalmology & Visual
Science, 41:73-81
7
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
(2000)) and angiogenesis (ZAGON et al., Journal of Vascular Surgery, 37:636-
643 (2003);
Blebea et al., Journal of Vascular Surgery, 32:364-373 (2000)), all of which
have been
implicated as factors in diabetic complications.
[0025] Interestingly, patients with T1D as well as mice with Type 2 diabetes
(T2D) have
elevated levels of OGF ([Metl-enkephal in) (Fallucca et al., Metabolism,
45:1065-1068 (1996);
Negri et al., Metabolism, 41:460-461 (1992); Kolta et al., Neuropeptides,
21:55-63 (1992);
Timmers et al., Diabetes, 35:1143-1151 (1986); Greenberg et al. Endocrinology,
116:328-331
(1985)), suggesting that diabetes is accompanied by an increase in an opioid
peptide associated
with an inhibition of cell replication. Hence, without being bound to any
particular theory, it is
postulated that excessive OGF-OGFr interaction retards wound closure such as
is found in
diabetes. Moreover, interruption of this activity by NTX is responsible, at
least in part, for
restoring related processes to a normal condition.
[0026] Conditions associated with delayed wound healing include diabetes (both
Type 1/insulin-
dependent diabetes, and Type 2/ non-insulin dependent diabetes), obesity,
increasing age of the
subject, coronary artery disease, peripheral vascular disease, wound
infection, cancer, and
immunosuppression including immune system compromise and immunosuppressive or
radiation
therapies. The use of administration of opioid antagonists such as NTX and
naloxone to promote
wound healing where any of these conditions is present in a subject is
encompassed by the
disclosure herein. The inventors have discovered that administration of opioid
antagonists
promotes wound healing even in normal subjects; thus the methods and
compositions of the
invention can be beneficial in any situation where improved epithelial wound
treatment is
desired. Without being bound, it is believed that the opioid antagonists
promote wound healing
in part through interaction with the opioid growth factor receptor (OGFr).
Accordingly, in one
embodiment, the methods and compositions provided herein are administered to
an epithelial
wound where OGFr is present or expressed on epithelial cells adjacent to or
forming the
epithelial wound.
8
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
[0027] The studies presented herein identify improved wound healing in both
T1D and T2D
model animals; thus the methods and compositions provided herein are
applicable to treatment of
epithelial wounds in a subject with any form of diabetes.
[0028] Subjects which can be treated using the disclosed methods include any
mammalian
subjects, particularly human subjects, dogs, cats and horses, which can be a
diabetic or non-
diabetic subject.
[0029] Epithelial wounds which can be effectively treated in accordance with
this disclosure
include epidermal wounds involving cells and tissue in the epidermis (such as
any of the five
epidermal layers: stratum basale, stratum spinosum, stratum granulosum,
stratum licidum, and
stratum comeum); dermal wounds involving cells and tissue in the dermis of the
skin; and
wounds involving interior epithelial surfaces of the body, such as the
epithelial lining of internal
organs and body cavities. Thus, the methods and compositions of the invention
can be used to
treat surface wounds such as skin abrasions, wounds involving injury to the
dermis and
epidermis, and also internal or subsurface wounds such as enhancing closure of
incisions
following a surgical procedure.
[0030] By "treating epithelial wounds" it is meant promoting, accelerating
and/or enhancing
wound closure, wound contraction, maturation and remodeling, fibroplasia and
granulation tissue
formation, and/or re-epithelialization.
[0031] An "opioid antagonist" binds to and antagonizes (prevents or inhibits
signaling of) opioid
receptors. Opioid antagonists include nalorphine, levallorphan, cyprodime,
naltrindole,
norbinaltorphimine, buprinophine, naltrexone and naloxone. Preferred opioid
antagonists are
antagonists that have affinity for, but do not activate, opioid receptors.
Examples of preferred
opioid antagonists include naltrexone and naloxone.
[0032] For purposes of the present invention, both naltrexone and naloxone, as
well as
pharmaceutically acceptable salts thereof (e.g., naltrexone hydrochloride, and
naloxone
hydrochloride) and prodrugs thereof, are suitable for use in the treatment of
epithelial wounds.
9
100331 The 1UPAC name of naltrexone is 17-(cyclopropylmethyl)-4,5a-epoxy-3,14-
Dihydroxymorphinan-6-one. Naltrexone can be described as a substituted
oxymorphone,
where the tertiary amine methyl-substituent is replaced with
methylcyclopropane. Naloxone
is also known as dihydroxymorphinan-6-one.
100341 By "prodrug" of a naltrexone and naloxone, it is meant a
pharmacological compound
administered in an inactive or less active form as compared to naltrexone and
naloxone; and
is converted in vivo into naltrexone or naloxone after administration. In some
embodiments,
the prodrug is converted into naltrexone or naloxone in not more than three
enzymatic steps.
In specific embodiments, the prodrug is converted into naltrexone or naloxone
in one or two
enzymatic steps. Examples of prodrugs of naltrexone include straight-chain
naltrexone-3-
alkyl ester prodrugs of 2-7 carbons in chain length described in Stinchcomb et
at., J.
Pharmaceutical Sciences 91: 2571-2578, 2002), as well as the ester, carbonate
and carbamate
prodrugs described in Valiveti et al., Pharmaceutical Res. 22: 981-989 (2005).
100351 The therapeutic method of treating epithelial wounds involves
administration of an
effective amount of naltrexone and/or another general opioid antagonist to the
epithelial area
of a subject for which treatment is desired. For example, treating skin wounds
involves
topical administration of an effective amount of naltrexone and/or another
general opioid
antagonist to the wounded area of the skin of a subject.
[0036] Topical administration includes directly applying, laying, or spreading
on or around
the wounded area, e.g., by use of an applicator such as a wipe, a dissolvable
film, a dropper, a
spray, or through the use of a wound dressing such as a patch.
[0037] The opioid antagonist can be combined with a pharmaceutically
acceptable carrier and
formulated for convenient topical administration. As used herein, a
pharmaceutically
acceptable carrier includes solvents, dispersion media, isotonic agents and
the like. Except
insofar as any conventional media, agent, diluent or carrier is detrimental to
the recipient or
to the solubility or therapeutic effectiveness of the opioid antagonist, its
use is appropriate.
The carrier can be
CA 2842337 2018-10-09
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
liquid, semi-solid, e.g. pastes, jelly or cream, or solid carriers. Examples
of carriers include
water, saline solutions, alcohol, sugar, gel, lipids, liposomes, resins,
porous matrices, binders,
fillers, coatings, preservatives and the like, or combinations thereof. The
opioid antagonist can
be combined with the carrier in any convenient and practical manner, e.g., by
admixture,
solution, suspension, emulsification, encapsulation, absorption and the like,
and can be made in
formulations such as tablets, capsules, powder, syrup, suspensions, emulsions,
ointments, gel,
jelly, cream, dressing, patches and the like, that are suitable for topical
administration.
[0038] In a specific embodiment, the opioid antagonist such as naltrexonc or
naloxone is
formulated as a solution or suspension and is applied topically in the form of
liquid drops. Any
solution suitable for topical application in which an opioid antagonist (such
as naltrexone or
naloxone) is soluble can be used; e.g., sterile water, Sorenson's phosphate
buffer, among others.
[0039] In another specific embodiment, the opioid antagonist is provided in an
aqueous-based
cream excipient, which can be applied to the wound skin area as a gel, cream
or ointment.
According to this embodiment, the opioid antagonist can be solubilized first
in a liquid carrier
(such as water or Sorenson's phosphate buffer), then admixed with a skin cream
or gel product.
[0040] In other specific embodiments, an opioid antagonist is combined with
and incorporated
into a solid carrier in the form of patch or dressing, suitable for topical
application to skin. In
some embodiments, the formulation or skin product is made to have properties
such as sustained-
release or improved stability. For example, a polymeric matrix composition
containing
naltrexone can be topically applied to the skin to achieve sustained release.
[0041] Compositions containing an opioid antagonist can include additional
ingredients,
additives or carrier suitable for use in contact on or around the epithelial
wounds without undue
toxicity, incompatibility, instability, irritation, allergic response, and the
like. Additives such as
solvents, bases, solution adjuvants, suspending agents, thickening agents,
emulsifying agents,
stabilizing agents, buffering agents, isotonicity adjusting agents, soothing
agents, preservatives,
corrigents, flavoring agents, coloring agents, excipients, binding agents,
lubricants, surfactants,
11
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
absorption-promoting agents, dispersing agents, preservatives, solubilizing
agents, and the like,
can be added to a formulation where appropriate.
[0042] The opioid antagonist-containing formulations or compositions of this
disclosure can
include other active ingredients or active agents for treating epithelial
wounds, including, but
not limiting to, anti-infective agents, antibiotics, antiviral agents, anti-
inflammatory drugs, anti-
allergic agents including anti-histamines, vasoconstrictors, vasodilators,
local anesthetics,
analgesics, intraocular pressure-lowering agents, immunoregulators, anti-
oxidants, vitamins and
minerals, proteases and peptidases that breakdown endogenous opioids, and the
like. In a
specific embodiment, an opioid antagonist-containing formulation also includes
insulin for
topical administration to wounded skin of a diabetic subject.
[0043] An opioid antagonist-containing composition of the present invention is
administered to a
subject in need thereof at an effective amount to treat the wounded epithelial
tissue of the
subject. The effective amount of the composition for a particular individual
can depend on the
size and depth of the wound, the type of formulation being applied, the
frequency of
administration, and the duration of the treatment. It has been found in
accordance with the
present invention that an opioid antagonist such as naltrexone, dissolved at
relatively low
concentrations in liquid (e.g., at least 10-6 M, at least 10-5M, or at least
104 M to 5 x 104 M, or
any concentration falling in a range between these values, when applied
through several different
carriers (liquid or semi-solid) to the wounded epithelial area, significantly
promotes wound
healing. For dermal/epidermal wounds, daily applications, preferably one to
three daily
applications, are preferred. The final concentration of the opioid antagonist
in the formulation
applied to a wounded area, whether liquid or semi-solid, is at least 0.003%
(w/w), and up to 5-
10% (w/w), and generally in the range of 0.1% to 5% (w/w).
[0044] The present invention is further illustrated by, but not limited to,
the following examples.
12
EXAMPLES
Materials and Methods
Animals and induction of diabetes
[0045] Male Sprague-Dawley rats (-150 g) were purchased from Charles River
Laboratories
(Wilmington, MA), and housed under standard laboratory conditions; water and
food were
available ad libitum. All investigations conformed to the guidelines of The
Pennsylvania State
University College of Medicine Institutional Animal Care and Use Committee.
[0046] Type I diabetes (T1D) was induced by intraperitoneal (i.p.) injections
of 40 mg/kg
streptozotocin (STZ, Sigma, St. Louis, MO), on two consecutive days (Klocek et
al., Journal of
Ocular Pharmacology and Therapeutics, 23:89-102 (2007); Havel et al.,
Diabetes, 49:244-252
(2000)). This regimen produced insulin-dependent diabetes in 100% of the
animals within 72-96
h; rats with blood glucose levels measuring >350 mg/di were considered
diabetic (DB). Blood
glucose levels were monitored from the tail vein using a True Track Smart
System glucometer
(Home Diagnostics, Ft. Lauderdale, FL) before receiving STZ, and at 1, 4, and
8 weeks
following induction of hyperglycemia. Control animals receiving an injection
of an equivalent
volume of sterile saline were termed "normal". All rats were weighed weekly.
Materials and Methods- Experiment I. Naltrexone and unwounded skin
Naltrexone application
[0047] Normal (n= 24) and diabetic (DB) rats (n= 24) were randomized 8 weeks
after injections
of STZ or saline, and received NTX (Sigma- Aldrich, Indianapolis, IN)
systemically (30 mg/kg,
i.p. or subcutaneous (s.c.) at 0800 h) or topically 3 times daily at 0700,
1200, and 1700 h. For
topical applications, NTX was dissolved in Sorenson's phosphate buffer (SPB),
KY jelly (trademark)
(KYJ) (K-Y, Personal Products Company, McNeil-PPC, Inc., Skillman, NJ),
Neutrogena (trademark)
moisturizing cream (MCN) (Neutrogena Corporation, Los Angeles, CA), or DMSO
(VWR,
Philadelphia, PA). NTX was dissolved in sterile water at dosages of 10"4 M,
105 M or 106 M, and
thoroughly mixed
13
CA 2842337 2018-10-09
into each of the carriers (1: 1, v/v); 0.5 ml of saline mixed into
corresponding carriers served as
the respective vehicle control.
[0048] On the day preceding NTX or vehicle treatment, an 8 x 8 cm area was
shaved on the
dorsal surface of each rat and 4 circles (approximately 20 mm in diameter)
were made with a
permanent marker to denote locations of subsequent topical applications and/or
skin collection.
Using an applicator stick, one ml of carrier containing NTX or vehicle was
placed within the
demarked areas. Applications of NTX formulations were randomized to different
positions.
Each animal received NTX in 3 different concentrations, as well as the
vehicle, in the same
carrier; some rats received only saline in a carrier or were untreated.
DNA synthesis
[0049] To assess cells undergoing DNA synthesis, rats were injected i.p. with
100 mg/kg BrdU
(Sigma-Aldrich) 3 and 6 h before euthanasia with Euthasol (Virbac, Fort Worth,
TX).
Appropriate regions of the skin were removed, fixed in 10% buffered formalin,
and paraffin
sections (6 girl) were stained with anti-BrdU-POD (Invitrogen, Carlsbad, CA).
BrdU stained
cells in the basal layer of the epithelium were counted in four 0.1 mm grids
at 250X
magnification using 2 sections/specimen; 3 tissue specimens were analyzed for
each dosage of
NTX in each carrier.
Materials and Methods- Experiment II. Naltrexone and wound healing
Full-thickness cutaneous wounds
[0050] In a second set of experiments, Normal (n=70) and DB (n=70) Sprague-
Dawley rats, 12-14
weeks of age and 8 weeks after injection of STZ, were subjected to wounding.
Eight rats/treatment
regimen were evaluated over the course of 3 independent experiments. The
dorsum of the rat was
shaved, and areas (20 mm in diameter) outlined with a marker in order to
consistently position the
wounds. Animals were anesthetized by i.p. injection of ketamine (60 mg/kg),
xylazine (10 mg/kg),
and acepromazine (1 mg/kg), and a 6 mm full-thickness circular excisional skin
wound was made in
the center of the demarked area to the level of the panniculus muscle using an
Acupunch (trademark)
(Acuderm Inc., Fort Lauderdale, FL). Three wounds per
14
CA 2842337 2018-10-09
rat were standardized such that the first wound was made 5 cm posterior to the
occipital notch
at the posterior of the animal's cranium and 1 cm off the midline. The second
wound was
created 7 cm posterior to the occipital notch at the posterior of the animal's
cranium and 1 cm
off the midline on the opposite side from the first wound. The third wound was
placed 9 cm
posterior to the occipital notch at the base of the animal's cranium and 1 cm
off the midline on
the same side as the first wound. To minimize the effects of diurnal rhythm,
surgery was
performed between 0800-0900 h. All wounds were left uncovered.
[0051] Topical administration of -0.1 ml of the carrier containing NTX or
vehicle, using the
dosage and carriers selected from the first experiment, was initiated
immediately after
wounding (0800 h for those rats receiving agents only once per day, and at
0800, 1200, and
1600 h for those animals receiving 3 applications daily); control rats
received the carrier with
vehicle either once or three times daily. Some animals in the Normal and DB
groups were
wounded but untreated.
Photography
[0052] Wound size was monitored by capturing images with a digital camera
mounted on a
tripod set 20 cm from the surface; a ruler was photographed with each wound.
Animals were
manually restrained without anesthesia for photography. Photographs were taken
immediately
after surgery and on days 3, 5, 7, 9, and 11. The area of each wound was
analyzed using Image
ProPlus 6.2 (trademark) (Media Cybernetics, Inc., Bethesda, MD). The percent
residual wound
was calculated at each time point for every rat. At 8 days, wound closure also
was quantified
according to Pietramaggiori and colleagues (Pietramaggiori et al., J Surg Res
160: 169-177
(2010)) by measuring contraction, re-epithelialization, and open wound as a
percentage of the
original wound area. The sum of contracted, re-epithelialized, and open wound
area was defined
as equaling 100% of the original wound size (Yannas I., Tissue and Organ
Regeneration in
Adults. New York: Springer, 2001).
CA 2842337 2018-10-09
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
DNA synthesis and histopathology
[0053] Cell proliferation was evaluated with BrdU on days 5 and 10 post-
wounding as
described above. The number of labeled and unlabeled cells in the basal layer
of the epithelium
was counted in four 0.1 mm grids at 250X magnification, and sampled from
regions adjacent,
and 0.5 mm peripheral, to the edge of the wound site. Three Normal and 3 DB
rats receiving
MCN+vehicle or MCN+NTX 3 times daily were injected with BrdU.
[0054] On day 20 following creation of the wound, some rats were euthanized
and the original
wound areas as well as tissue peripheral to the wound that encompassed the 20
mm diameter
circle were excised and fixed in 10% neutral buffered formalin. Tissues were
processed for
paraffin embedding; sections were stained with hematoxylin and eosin. The
thickness of the
epithelium covering the granulation tissue was measured with an ocular
micrometer. Five
measures/section from 7-8 wounds/treatment group were evaluated at 250X
magnification.
Data analysis
[0055] Body weights and glucose measurements were analyzed with Student's two-
tailed t-test.
Areal measurements of defects (e.g.. percent residual wound, contraction),
thickness of the
epithelium, and DNA labeling indexes were evaluated using analysis of variance
(ANOVA) with
subsequent planned comparisons made utilizing Newman-Keuls tests.
RESULTS
Experiment 1. Naltrexone and unwounded skin
[0056] All rats were hyperglycemic within 72 h of STZ injection, with blood
glucose levels for
Normal and DB animals being 119 4 and 569 9 mg/dL, respectively (Fig. 1).
The body
weights of DB rats were reduced by 8% to 28% from Normal cohorts beginning 1
week after
STZ injection and continuing throughout the experimental period (Fig. I). Rats
in the DB
group were not provided with insulin. No animals died from hyperglycemia.
[0057] Relative to the BrdU labeling index of 8.1 0.3% in basal cells of the
cutaneous
epithelium of Normal rats, systemic injections of 30 mg/kg NTX by the i.p. or
s.c. routes
16
CA 02842337 2014-01-16
WO 2013/016480 PCT/1TS2012/048236
elevated BrdU labeling by 172% and 51%, respectively. With respect to a
labeling index of 8.1
0.5% in the skin of animals with DB, i.p. and s.c. injections of NTX increased
BrdU
incorporation by 181% and 59%, respectively.
[0058] The effects of topical application of NTX (10-4 M to 10.6 M) dissolved
in four different
carriers that had different properties (e.g., absorption, density) were
examined in Normal and
DB rats (Fig. 2). Topical NTX dissolved in any of the 4 carriers consistently
elevated (43-
132%) DNA synthesis from baseline levels in Normal animals. Animals receiving
NTX in SPB
displayed the lowest level of increase in BrdU incorporation in the skin (43-
56%) compared to
baseline values, whereas rats treated with different dosages of NTX in MCN
exhibited some of
the greatest changes from baseline (73-132%). In the DB rats, topical exposure
to NTX at all 3
dosages markedly elevated labeling indexes from baseline levels when delivered
in KYJ (103-
147%) or MCN (85-89%). NTX at concentrations of 10-/ and 10-5 M delivered in
SPB to DB
rats had no effect on BrdU incorporation. The opioid antagonist combined with
DMSO only
was efficacious at concentrations of 10-4 and i05 M.
[0059] To examine whether topical application of NTX had systemic
ramifications, some rats
were treated with MCN+NTX (10 5 M) or MCN+vehicle at different positions on
their dorsum.
The skin treated with MCN+NTX had a labeling index of 18.0 0.9% compared to
8.1 0.7%
for wounds on the same animal receiving MCN+vehicle; the basal epithelium of
separate,
untreated rats had a labeling index of 8.2 0.5%.
[0060] Examination of the skin, both grossly and by histological measures,
revealed a similar
appearance in Normal and DB rats receiving vehicle or any dosage of NTX in any
carrier. The
morphology of the treated skin was comparable to that in animals not exposed
to any agent
(Fig. 3).
Experiment 11. Naltrexone and full-thickness wounds
[0061] Based on the labeling index data from the first experiment, NTX at 10-5
M applied in
two topical delivery systems. KYJ and MCN, was chosen for subsequent
experiments
17
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
examining the effects of opioid antagonist blockade on full-thickness wound
healing. Normal
and DB rats expressed body weight and glucose patterns similar to those in
Fig. 1. All rats
tolerated the wounding procedure without problems (e.g., normal food
consumption).
Normal and diabetic wound healing
[0062] Using a 6 mm trephine, the calculated wound size was 28.3 mm2, and
wounds that
deviated more than 10% were not included for analysis. Evaluation of wound
closure in
Normal and DB rats revealed that the area of residual wound in DB animals was
24%, 44%,
and 132% greater on days 5, 7, and 9 following surgery relative to those of
Normal rats (Fig.
5A).
Number of applications of NTX and efficacy of wound healing
[0063] To examine the effects of topical application of NTX on the healing of
full-thickness
wounds in Normal and DB rats, an investigation was initiated to study whether
the number of
daily applications of NTX was critical (Figs. 4, 5). Within 3 days of a single
or three times
daily regimen of 10-5 M NTX in MCN to Normal rats, wound areas were reduced
30% and
11%, respectively, relative to that of animals receiving MCN+vehicle (Fig.
5B). Wound sizes
on days 3, 5, 7, and 9 in NTX-treated Normal animals were smaller than in
cohorts receiving
MCN+vehicle, with reductions ranging from 31-82% and 11-23% for the one and
three times
daily regimens, respectively; all data were statistically significant except
for the value for the
three times daily group on day 9. DB animals subjected to once daily
application of
MCN+NTX also had a decrease in wound size compared to DB rats exposed to
vehicle, but
with only 32% and 42% reductions recorded on days 5 and 7, respectively.
However, in regard
to the DB animals, MCN+NTX given three times daily consistently accelerated
wound closure,
with this group displaying mean residual wounds that were reduced 13% to 57%
from DB rats
treated with MCN+vehicle.
[0064] In addition to absolute wound closure, wound contraction and re-
epithelialization, two
of the main mechanisms contributing to healing (Pietramaggiori et al., Journal
of Surgical
Research, 160:169-177 (2010); Yannas, Tissue and Organ Regeneration in Adults,
New York:
18
=
Springer (2001)) were analyzed on day 8 in the MCN group (Fig. 5C). DB rats
receiving
MCN+vehicle had an open wound 82% larger than that of Normal animals treated
with
MCN+ vehicle, and rates of wound contraction were reduced by 38%; re-
epithelialization,
however, was comparable between these two groups. DB rats subjected to MCN+NTX
were
similar in all parameters (i.e., wound size and contraction, re-
epithelialization) to that of
Normal animals given MCN+vehicle, with the size of the open wound and wound
contraction
of DB animals treated with MCN+NTX being one -half that of DB animals treated
with
MCN+vehicle.
100651 To examine whether the effects of NTX on wound closure were dependent
on a
particular type of moisturizing cream (i.e., Neutrogena (trademark)), some
animals were treated with
NTX in Oil of Olay (trademark) (MC00) (Procter & Gamble, Cincinnati, OH). In
comparison to
Normal animals exposed three times daily to MCOO+vehicle, those rats receiving
l0'5 M NTX
in MCOO had 24 to 65% smaller residual wounds on days 5, 7, and 9 (Fig. 6). DB
animals
subjected three times daily to MCOO+NTX had wounds that were 33-80% smaller
than
counterparts receiving MCOO+vehicle on days 5, 7, and 9.
100661 To address the question whether the action of NTX was reliant only on
moisturizing
creams, Normal and DB rats were treated three times daily with NTX in KYJ
(Fig. 6). Wounds
in Normal animals receiving KYJ+NTX were 10-17% smaller on days 3 and 5
relative to
wounds treated with KYJ+vehicle. In contrast to DB rats receiving vehicle in
KYJ, DB animals
subjected three times daily to KYJ+NTX had wounds that were 15-65% smaller on
days 3, 5. 7,
and 9.
Histopathology
[00671 The overall pathology of the wounded region 20 days following surgery
was evaluated with
hematoxylin/eosin stains (Figure 7). The general structure of the epithelium
between Normal and DB
rats receiving vehicle or NTX appeared to be similar (e.g., absence of
necrotic cells). However, in
comparison to a width of the epithelium overlying the granulation tissue of
24.6 + 1.6 jam in Normal
rats, DB rats receiving vehicle had a 44% reduction. Normal animals
19
CA 2842337 2018-10-09
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
treated with NTX, as well as DB rats subjected to NTX, did not differ in the
thickness of the
epithelium relative to Normal animals receiving vehicle.
DNA Synthesis
[0068] In order to begin to decipher the mechanism of NTX action with respect
to wound
healing in DB mice, and keeping in mind previous reports that NTX targets cell
proliferation
(Zagon et al., Journal of Invest Dermatology, 106:490-497 (1996); Zagon et
al.. Diabetes,
51:3055-3062 (2002); Zagon et al., Journal of Vascular Surgery, 37:636-643
(2003); Blebea et
al., Journal of Vascular Surgery, 32:364-373 (2000); Zagon et at.,
Imrnunobiology, 216:173-
183 (2011); Zagon et al., Immunobiology, 216:579-590 (2011); Wilson et al.,
Cell Prolif, 33:63-
73 (2000)). Normal and DB rats subjected 3 times daily to vehicle or 10-5 M
NTX in MCN
were assessed for BrdU labeling on days 5 and 10 following wounding (Fig. 8);
skin adjacent
and peripheral to the site of injury was evaluated. MCN+NTX altered DNA
synthesis in the
basal epithelium of skin adjacent to the wounds, but not in the peripheral
region in both DB and
Normal rats. In the DB rats, those treated with MCN+NTX had a 72% and 36%
increase in
labeling index on days 5 and 10, respectively, in skin adjacent to the wound.
In Normal
animals there was an increase of 30% and 69% on days 5 and 10, respectively,
in labeled cells
located in skin adjacent to the wound of Normal rats compared to cohorts
receiving vehicle.
Experiment III.
[0069] To study the effects of opioid antagonists on wound healing in a Type 2
diabetic and
general obesity model, wound healing was compared between wild type and Leprdb
(also
referred to as db/c113) mutant mice. Mice homozygous for the diabetes
spontaneous mutation
(Leprab) become identifiably obese around 3 to 4 weeks of age. Plasma insulin
levels become
elevated beginning at 10 to 14 days and blood sugar levels become elevated
beginning at four
to eight weeks. These mice show delayed wound healing compared to wild type
mice.
[0070] Mice were purchased from Jackson Laboratories and housed under standard
laboratory
care. Body weights and blood glucose levels of 8-week old Type 2 diabetic
(dbldb) mice and
wild type C57B1/6 mice were obtained (Figure 9). Tail vein blood was obtained
and glucose
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
levels were measured by a TrueTrak glucometer. Values represent means SEM;
n= 6-10
mice/treatment group. Data were analyzed using t-tests; significantly
different from wild type at
p<0.001 (***). As seen in Figure 9, eight week-old db/db mice have
significantly higher body
weight and blood glucose levels than wild type C57B1/6 mice.
[0071] To study wound healing, a 5-mm circular full-thickness cutaneous wound
was created
on the dorsum of db/db and wild type mice. Db/db mice were treated with either
IV M
Naltrexone (NTX) in moisturing cream (vehicle), or vehicle alone; wild type
mice received
vehicle only. Applications were made 3 times daily for 15 days. As seen in
Figure 10, db/db
mice show a significantly higher percent residual defect on days 3, 6, and 13
following wound
formation, relative to wild type. However, db/db mice treated with NTX show
significant
improvement in would healing relative to db/db mice treated with vehicle only
by days 6, 13,
and 15. Significantly different from wildtype vehicle values at p<0.01 (++).
Significantly
different from db/db vehicle values at p<0.05 (*).
[0072] These studies show that topical NTX treatment improves wound healing in
Type 2
diabetes in addition to Type 1 diabetes. In addition, as db/db mice are also a
model for obesity
in general, this study show that topical opioid antagonists are beneficial not
only for treating
wounds in the diabetic population, but for treatment of wounds in a normal
population as well.
DISCUSSION
[0073] With the use of a well-characterized model of T1D wherein rats
developed typical
physiological characteristics observed in diabetic humans such as
hyperglycemia, weight loss,
and poor wound healing (Zagon et al., Diabetes, 51:3055-3062 (2002); Klocek et
al., Journal of
Ocular Pharmacology and Therapeutics, 23:89-102 (2007); Havel et al.,
Diabetes, 49:244-252
(2000)), a major finding in this study is that disruption of endogenous opioid-
opioid receptor
interfacing with the opioid antagonist NTX can increase DNA synthesis in basal
epithelial cells
of the skin in T1D animals, as well as normal (non-diabetic) cohorts. The
effects of NTX on
cell proliferation were not toxic, relatively short-acting, and not dependent
on either
concentration (within a 100-fold range applied topically) or route of
administration (systemic or
21
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
topical). NTX administered by topical delivery was localized in influencing
DNA synthesis, as
cells subjacent to the carrier with drug were elevated in BrdU labeling but
not basal epithelial
cells distant from NTX application.
[0074] Since NTX is a pure opioid antagonist and devoid of direct biological
action (Blumberg
et al., Agonist and Antagonist Actions of Narcotic Analgesic Drugs, 110-119
(1973); Sawynok
et al., Life Science, 25:1621-1632 (1979)), the upregulation of DNA synthesis
by interruption of
opioid peptide-opioid receptor interfacing indicates that one or more
endogenous opioid
systems present in human and animal cutaneous epithelium (Zagon et al.,
Journal of Invest
Dermatology, 106:490-497 (1996)) are intact and function as tonically active
repressors of
DNA synthesis under pathophysiological conditions related to T ID. Although
some studies
report that epithelium (e.g., ocular surface) of T1D animals has a subnormal
level of DNA
synthesis (Zagon et al.. Diabetes, 51:3055-3062 (2002)), it is interesting to
note that the basal
layer of epithelial cells in the skin of diabetic animals had a rate of DNA
synthesis comparable
to that of normal rats, suggesting that at least 2 months after the induction
of diabetes,
abnormalities in cell replicative events were not evident in the skin.
[0075] Based on these initial experiments, the inventors characterized the
effects of this agent
on repair of full-thickness cutaneous wounds in T1D and T2D animals.
Evaluation of closure
rates showed that the wounds of diabetic animals were significantly slower to
heal than those in
normal animals, and that topical NTX placed in these carriers restored the
rate of wound
closure to levels comparable to and often exceeding that of normal animals.
Animals with
diabetes had markedly reduced wound contraction compared to normal cohorts,
but T ID and
T2D animals receiving topical NTX were comparable to normal subjects. The
structural
appearance of the closed wounds in the diabetic animals receiving NTX was
similar to that of
normal animals, indicating that the increased rate of wound repair was not
accompanied by
abnormal morphological events. Although once daily application of NTX was
sufficient to
increase the rate of cutaneous wound closure in DB rats, three daily
applications were superior.
22
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
[0076] The successful use of NTX for topical delivery demonstrated herein
raises the question
of whether this drug has systemic repercussions. NTX is a small hydrophilic
molecule that has
been suggested to not have physicochemical properties necessary to achieve
therapeutic doses
for transdermal delivery (Wermeling et al., Proc Nati Acad Sci USA, 105:2058-
2063 (2008);
Stincheomb et al., Journal of Pharm Science, 91:2571-2578 (2002)). but is
known to enter
human and animal cells rapidly by passive diffusion (Cheng et al., American
Journal of
Physiology, 297:R844-R852 (2009)). The studies presented herein reveal that
NTX had a
localized but not systemic action, with DNA synthesis altered only at the site
of delivery.
Moreover, the inventors employed a very small concentration of NTX that is non-
toxic, but
highly efficacious in terms of wound repair. Thus, in considering the
application of topical
NTX for the treatment of wounds clinically, these studies show that this is
feasible in terms of
biocompatability, and lack of toxicity and systemic action. Additionally,
problems in
compliance should be minimized by the localized effects of this opioid
antagonist.
[00771 The present finding that an opioid antagonist can restore the delayed
rate of cutaneous
wound healing recorded in diabetes to that of normal animals has some
parallels with previous
reports concerning corneal re-epithelialization in T1D rats (Zagon etal.,
Diabetes, 51:3055-
3062 (2002); Klocek et al., Journal of Ocular Pharmacology and Therapeutics,
23:89-102
(2007)). These include: i) efficacy of both topical and systemic NTX routes of
delivery, ii)
response to similar concentrations (e.g., 10-5M) of NTX, iii) NTX-induced
increases in the rate
of wound closure for both diabetic and normal animals, iv) necessity for
multiple daily
applications of NTX to achieve optimal healing rates, and v) DNA synthesis as
a principle
target for NTX action. However, some differences between the skin and cornea
of diabetic and
normal animals as to NTX's effects on wound healing should be noted. First,
corneal wound
healing is confined to the ocular surface epithelium and is reliant on re-
epithelialization. In
contrast, full-thickness cutaneous wound repair is related to both the
epithelium and the stroma,
and contraction plays a major role in repair. Second, the carrier for NTX in
the cornea included
an antibiotic, while no antibiotics were employed in the present study,
although inclusion of an
antibiotic and/or other additional component is contemplated for the invention
described herein.
Both studies show that heightened opioid peptide - opioid receptor interaction
as it relates to
23
CA 02842337 2014-01-16
WO 2013/016480 PCT/US2012/048236
DNA synthesis and wound healing occurs in T ID, and blockade of this
interfacing is
demonstrated to reverse the delayed repair of cutaneous, as well as corneal,
wounds in a
hyperglycemic environment.
[0078] The present results demonstrate that opioid receptor blockade can
reverse delayed
wound healing, such as is present in diabetes, to normal levels, indicating
that endogenous
opioid systems contribute to delayed wound healing. The glucose levels of the
diabetic rats in
this study were not only extraordinarily high compared with those of humans,
but the duration
of hyperglycemia was sustained for 3 months, emphasizing the magnitude of the
diabetic
condition. The data suggest that even in the face of such uncontrolled
diabetes, wound healing
could be restored with topical NTX. This finding provides evidence that the
action of NTX
must be extremely potent, and that opioid-receptor interactions are capable of
being disrupted
by NTX in animals with persistently high glucose levels.
[0079] Impaired wound healing is a major complication in both T1D and T2D (Guo
et al.,
Journal Dent Res, 89:219-229 (2010); Boulton et al., Lancet, 366:1719-1724
(2005);
O'Loughlin et al., International Journal of Lower Extremity Wounds, 9:90-102
(2010); Usui et
al., Journal of Hislochem Cytochem, 56:687-696 (2008)). The studies herein
represent a
paradigm shift regarding the etiology and pathogenesis of complications from
diabetes by
identifying opioid peptides and opioid receptors as key players in this
disease. It is important to
recognize that NTX is an FDA-approved drug used at far higher dosages in the
treatment of
addiction (e.g., drug abuse, tobacco, gambling) (Kirchmayer et al., Addiction,
97:1241-1249
(2002); Swift. American Journal of Health Syst ['harm, 64:S12-S22 (2007)). In
addition, an
ongoing Phase I clinical trial is assessing the safety of topical NTX in the
eye for the treatment
of diabetic keratopathy, and the results heretofore indicate that NTX is
without toxicity. The
utilization of small dosages of NTX in a topical application with localized
but not systemic
effects eliminates any potential adverse events, even for patients using
opioids for pain
management.
24
